Erba Molecular continues the expansion of its team with the appointment of Dr Sarah Mardle as Director of Quality & Operations 

 

Cambridgeshire, UK, 1 December 2016 Erba Molecular (previously known as Lumora Limited), a successful provider of state-of-the-art molecular diagnostic products into both the clinical and industrial markets, is pleased to announce that it has appointed Dr Sarah Mardle as Director of Quality & Operations. 

Sarah will be responsible for leading and managing the strategic and operational performance of the Quality and Operations department, specifically working towards ISO13485 compliance. Prior to working for Erba Molecular, Sarah was employed by Baxter Inc, where she was responsible for the Compounding Unit (manufacturing chemotherapy, antibiotics, total parenteral nutrition pharmaceuticals) compliance to GMP standards as part of the site leadership team, in addition to managing the QA, QC and microbiology teams.  Prior to working at Baxter, Sarah held senior QA and Operations positions at Biocair and Abcam. 

Sarah joins a growing team at Erba Molecular’s Ely based facility which in 2016 has seen a number of new R&D appointments including that of Vivian Jonas, Senior Director of Development, a TB and mycobacterial expert with over thirty years of infectious disease molecular diagnostics experience. 

Commenting on the new appointment Laurence Tisi, Chief Executive Officer of Erba Molecular said “Sarah is a fantastic addition to the team.  Her regulatory standards knowledge coupled with her extensive operational experience in rapidly expanding biotech companies will enable us to deliver quickly our growing molecular diagnostics product development pipeline in a regulatory framework.  2016 has been a pivotal year of growth for the company, putting us in an optimum position for delivering on our objectives in 2017”. 

Sarah commented “I am delighted to join the Erba team and look forward to working at the cutting edge of science to develop innovative diagnostics”. 

Sarah has a Neuroscience PhD from King’s College London and a BSc Double Honours Biochemistry & Pharmacology from the University of Southampton. 

-ends- 

Notes to Editors: 

About Erba Molecular 

Erba Molecular (previously known as Lumora Ltd) is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets.  In September 2015, Lumora Ltd was acquired by Erba Diagnostics Mannheim a fully integrated global in vitro diagnostics company, offering a comprehensive suite of clinical testing products to the growing number of smaller hospitals, reference labs, and physician clinics in the developed and emerging markets with reliable, 

affordable and innovative health care products. Erba Diagnostics Mannheim is based in Mannheim, Germany and serves more than 25,000 customers spread across 100+ countries through its 1500+ committed employees and an extensive distributor network.  

For more information, please visit: 

www.erbamdx.co.uk 

www.erbamannheim.com 

 

Patent Published for Lumora’s Novel Sample Preparation Technology

Cambridgeshire, UK, 31 October 2013 ...

 

Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has received a patent for its Heat Elution Sample Preparation, technology which has the potential to help commercial laboratories simplify the process and save valuable time and money in sample preparation.

The new sample preparation technique, Heat Elution, uses the power produced by heat lysis in a sealed vessel to drive elution through inhibitor removing materials, a by-product of sample preparation. By adding the sample to inhibitor removing materials in a sealed environment, the pressure caused by the heat lysis is able to cause elution, the process of separating the materials for testing. This means there is no need for complex and costly robotics or pumps, yet nucleic acids are produced in a suitably pure form ready for PCR or isothermal amplification. The process also combines purification with the heat lysis step, removing several steps from the sample preparation.

In addition to reducing the time needed for sample preparation, studies have indicated that this process may well improve sensitivity compared with traditional techniques.

The international patent number is International Patent Application No. PCT/GB2013/050846.

Laurence Tisi, CEO of Lumora said: “Sample preparation is a significant part of any scientists work when testing samples. Current techniques can be complex, labour intensive and expensive. We believe that this technique along with other sample prep technologies we are developing will help save a significant amount of time, effort and cost. Our aim is not only to make sample preparation easier and allow it to be done in non-specialised facilities, meaning it could be easily deployed in the developing world for tackling diseases such as HIV.”

Hayden Jeffreys, Commercial Director of Lumora, added: “Anything that reduces the time spent in sample preparation could provide significant cost savings to commercial labs by reducing the amount of time required for testing. Not only does this process reduce the time required for sample preparation, data also shows that it has an increased sensitivity when compared with traditional sample preparation.”

The patent news is another milestones for Lumora this year, which also includes a deal with Promega to provide re-agents, a deal with Biogal to provide veterinary diagnostics and a partnership with FIND (Foundation for Innovative New Diagnostics) to develop a novel malaria diagnostic.

-ends-

For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:

About Lumora
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.
www.lumora.co.uk

Lumora Signs Supply Agreement with Promega for Ultra-Glo Luciferase, to be used in Lumora's BART Molecular Diagnostics Technology

Cambridgeshire, UK , 22 July 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, and Promega, a leader in providing innovative solutions and technical support to the life sciences industry, have signed a supply agreement for the use of Promega's Ultra-Glo™ luciferase in Lumora's BART (Bioluminescent Assay in Real-Time) molecular diagnostics technology.

Lumora's BART technology is a novel reporter system, designed to be used with isothermal nucleic acid amplification technologies - primarily as a tool in molecular diagnostics. This is the first commercial molecular diagnostic application for Promega's Ultra-Glo luciferase, highlighting the potential of the bioluminescent enzyme when combined with cutting edge technologies such as BART.

Hayden Jeffreys, Commercial Director at Lumora, said: "This is a significant deal for both parties as it showcases the application of Ultra-Glo, a highly regarded reagent, in the fast growing area of molecular diagnostics. Promega has established itself as one of the best suppliers of reagents in the world, and by leveraging their global presence, combined with the potential applications of BART and Ultra-Glo, we believe this deal could be the start of a significant partnership."

Laurence Tisi, CEO of Lumora, said: "The BART technology represents the first of a new generation of bioluminescent assays which take advantage of the ability of Ultra-Glo to operate at temperatures in excess of 60˚C. BART bridges bioluminescent and molecular technologies in a unique way offering a breakthrough in the simplicity and robustness of molecular assays."

Matthew Cook, Head of Commercial Sales, Promega, added: "We are very pleased to collaborate with Lumora. The company has some excellent technologies in the molecular diagnostics space, which combined with Ultra-Glo has the potential to open new markets."

The BART technology causes a sample to emit light when a diagnostic test result is positive, making the technology extraordinarily simple to implement and eliminating the need for highly sensitive light detection apparatus. The simplicity of BART enables easy-to-use, affordable, robust hardware to be used. This is a major break-through as molecular diagnostics is typically associated with complex and expensive hardware.

This deal follows a series of milestones for Lumora this year, including a deal with Biogal to provide veterinary diagnostics, a partnership with FIND (Foundation for Innovative New Diagnostics) to develop a novel malaria diagnostic, a new fundraising round and the appointment of new team members including a new commercial director and Chairman.

-ends-

For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:

About Lumora
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora's easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very
active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora's corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.

www.lumora.co.uk

About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com

Latest scientific studies highlight the effectiveness of LAMP based diagnostics

 

 

New scientific studies have shown that LAMP (Loop Meditated Isothermal Amplification) based technologies could have a significant role in dealing with endemic diseases such as malaria.

The peer reviewed research which appeared in the Journal of Infectious Diseases shows how LAMP can be used as a tool or the quick and easy diagnosis of malaria in both modernized laboratories and in the field in areas of the world where the disease is endemic.

The studies highlighted the potential of Lumora’s work in this area, and its recent deal with FIND (Foundation for Innovative Novel Diagnostics) which will see the development of a new malaria test using BART (Bioluminescent Assay in Real Time), a technology based on LAMP .

 "Using this test requires only a room with very basic laboratory facilities, i.e. electricity," Iveth Gonzalez, a scientific officer and project manager of LAMP projects for malaria and Chagas disease at FIND, and an author on the studies, told PCR Insider. "This test can be used in any microscopy-level clinic in resource-poor nations and doesn’t need standard infrastructure for PCR."

"The current LAMP kit has been developed for case management, and small groups of samples can be tested simultaneously," Gonzalez said. "FIND is working with Lumora [to develop] the next generation of the assay which is a high-throughput format that will allow testing of bigger groups of samples. The application of this assay will mainly be for population screening in elimination campaigns."

In April, Lumora agreed a partnership with FIND to develop a rapid, high-throughput malaria diagnostic assay for screening patients in the developing world.

Lumora agrees licence and development program for Veterinary applications with Biogal Galed Labs

Cambridge, UK, Tuesday 28th May 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has entered into a license and development agreement with Biogal Galed Labs ACS Ltd, a provider of veterinary diagnostics, to develop a series of veterinary tests.

The partnership will allow Biogal Galed Labs ACS Ltd to access Lumora’s enabling technologies such as BART (Bioluminescent Assay in Real Time), as well as  the company’s proven know-how in test development, reader technologies and manufacturing.

The partnership will involve a significant pipeline of test development, starting with Leptosporis, a zoonotic bacterial infection transmitted through the urine of animals. Financial details were not disclosed.

Hayden Jeffreys, Commercial Director at Lumora, said: “This partnership further illustrates the broad utility of Lumora’s technology. The simplicity, robustness and ease of use, make BART and our other technologies very applicable to the non-traditional molecular environment, whether this in the industrial applications or in the clinical market.”

Laurence Tisi, CEO of Lumora, added:  “This deal with Biogal will showcase the benefits of working with Lumora’s expert team and its focus on delivering partner’s products to market in the shortest time possible.  With the Leptosporosis test progressing through development, we have already initiated work on a series of additional assays in the planned development pipeline.”

A spokesperson from Biogal commented, “We are excited to be able to partner with Lumora. They have an excellent track record of producing high quality assays for their partners, across a wide range of applications. Through this partnership we aim to provide our customers with advanced diagnostics which can be provided in all sizes of veterinary labs.”

The deal with Biogal follows a series of milestones for Lumora this year, including a partnership with FIND (Foundation for Innovative Novel Diagnostics) to develop a novel malaria diagnostic, a new fundraising round and the appointment of new team members including a new commercial director and Chairman.

-ends-

For further information please contact:

Tony Stephenson, Director

Exitus Communications

Tel: +44 (0)7899 796655

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Notes to Editors: 

Lumora

Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.

 

www.lumora.co.uk

Biogal Galed Labs ACS Ltd

Biogal, is a private company owned by Kibbutz Galed and is headquartered in northern Israel. It was established in 1986.Biogal – Galed Laboratories is dedicated to the development, manufacturing and marketing of excellent diagnostic tools for companion animals, poultry, farm animals and laboratory rodents. Customer oriented services lead us forward in our search for excellence, efficiency and innovation.

http://biogal.co.il/

Lumora to partner with FIND to develop new, high-throughput Malaria molecular diagnostic test for use in the developing world

Cambridge, UK, 15th April 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has partnered with The Foundation for Innovative New Diagnostics (FIND) to develop a rapid, high-throughput malaria diagnostic assay for screening patients in the developing world.

The partnership will allow FIND to access Lumora’s technologies such as BART (Bioluminescent Assay in Real Time) and the company’s expertise to develop a novel test that will allow rapid screening on a large scale.

Strategies for the elimination of malaria are held back by lack of screening technologies for use in the field that can detect hidden or low parasitemia malaria infections, and thus stamp out the final cases. Such screening would also then help to keep these populations malaria free. The first field test with sufficient sensitivity to detect as few as one malaria parasite in a finger-prick blood sample has recently been developed and released by FIND and Eiken Chemical (Japan). The partnership with Lumora, funded by the BMBF of Germany, will enable the malaria LAMP test to be scaled into a high-throughput screening test specifically designed for malaria elimination programmes.
 
Laurence Tisi, CEO of Lumora, said: “This partnership illustrates that by combining the versatility and strength of Lumora’s technologies, with the expertise of the team, we can develop a diagnostic which can be deployed in both a traditional and non traditional clinical setting . We are extremely pleased that FIND have recognised that Lumora’s approach of simplifying molecular diagnostics, through the application of its proprietary technologies such as BART, will bring significant benefit not only to the clinical market but more importantly to those who work in malaria control and elimination.”

“This partnership opens the way to fill one of the major gaps in the malaria elimination agenda”, said David Bell, head of the malaria and acute fever programme at FIND. “LAMP technology has already proven to be the most robust field technology for high-sensitivity diagnosis, currently entering programmes for elimination of both malaria and sleeping sickness and under development for a number of other diseases. Adding this high-throughput platform opens the way for a range of new diagnostic screening applications that could prove pivotal in managing several diseases of both human and animal health.”
 
Hayden Jeffreys, Commercial Director at Lumora, added: “We see the partnership with FIND as an important stepping stone to providing a greater menu of products utilising our technology in clinical setting s to complement our HIV portfolio, which includes Lumora’s viral load test. We look forward to extending this partnership in order to commercialise this product and the many others in our pipeline.”

-ends-

For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:

Lumora
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very
active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Cambridge Enterprise, (University of Cambridge) Tate Lyle Ventures LP, and Catapult Venture Managers Ltd.

www.lumora.co.uk

FIND
The Foundation for Innovative New Diagnostics is dedicated to developing affordable, easy-to-use and cutting edge diagnostic tests that save lives in the poorest areas of the world. From proof of principle to putting new tests into practice, the organization works with multiple and diverse groups, from academia, industry, donors, partners in the field, Ministries of Health and the World Health Organization. With new diagnostics for malaria, TB and sleeping sickness already in use, FIND is also working on other neglected diseases, such as Chagas disease and leishmaniasis and other causes of acute fever. Launched in 2003, the not-for-profit Foundation is ISO certified and financed by both the private and public sectors, including the Bill & Melinda Gates Foundation, Government of the Netherlands, the European Union, UNITAID, UK Department for International Development, National Institutes of Health (USA), UBS Optimus Foundation and others.

http://www.finddiagnostics.org/

News